SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Verge Genomics, a clinical-stage, tech-enabled biotechnology company pioneering the use of artificial intelligence (AI) and human data to transform drug ...
Late-stage cancer incidence may be a suitable alternative endpoint to cancer-specific mortality in lung and ovarian cancer screening trials, but not in breast, colorectal, or prostate cancer screening ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback